• Aerin Medical announced July 2026 FDA clearance updating RhinAer labeling with SOOTHE study findings in chronic rhinitis patients with comorbid migraine.
• Results from the prospective, single-arm study were already presented at two otolaryngology conferences in 2026.
• A single procedure reduced migraine frequency, acute medication use and severe migraine-related disability, with benefits sustained through one year.
• RhinAer is commercially available for chronic rhinitis; national commercial availability for patients with comorbid migraine is expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aerin Medical Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.